Global Contrast Media Injectors Market - 2022-2029

Global Contrast Media Injectors Market - 2022-2029

Market Overview

The global contrast media injectors market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.8% during the forecast period (2022-2029).

Contrast media injectors are medical devices utilized for injecting contrast media into the human body to increase the visibility of tissues for medical imaging procedures. Due to technological advancements, automated systems control the amount of contrast media agents used and promote automated data collection and personalized doses for each patient.

Market Dynamics

The contrast media injectors market growth is driven by the rise in trauma cases, rising diagnostic imaging centers, increasing the geriatric population, and research and development activities.

The rising prevalence of cardiovascular diseases is expected to drive the market growth

Technological advancement and rising radiological procedures are expected to boost the market over the forecast period. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. The increasing number of patients with cardiovascular disease that need to be diagnosed leads to increasing demand for contrast media injectors.

In addition, the market players are adopting market strategies, including product launches and collaboration. For instance, in December 2021, Qaelum NV partnered with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks. Also, in May 2020, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago. It was authorized by the FDA and vended in cooperation with GE Healthcare.

The adverse effects of contrast media will hamper the growth of the market

However, side effects of radiographic contrast media range from mild inconveniences, such as itching, to a life-threatening emergency. Contrast-induced nephropathy is an adverse reaction associated with the use of intravenous or intra-arterial contrast material. In addition, adverse reactions such as delayed anaphylactic reactions, allergic reactions, and cutaneous reactions.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global contrast media injectors market. According to an article published in Radiology Journal in April 2020, during the pandemic, economic imbalances resulted in decreased healthcare expenditures. Radiology companies have never experienced an economic shock that is simultaneously worsened by the need to limit the availability of imaging. Outpatient-heavy practices felt the biggest impact of these changes, but all imaging volumes decreased. Radiology practices should anticipate a 50%-70% decrease in imaging volume that lasts a minimum of 3-4 months, as per the location of practice and the stringency of the COVID-19 pandemic in each region. During the pandemic, many patients faced access to healthcare treatment, leads to a negative impact on the market.

On the other hand, in 2022, the situation is recovering COVID- 19, and mostly every patient can access advanced healthcare facilities. Diagnostic centers are opening properly, and giving services to patients boosts the market worldwide.

Segment Analysis

The CT segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The CT segment is expected to boost the market over the forecast period. As per the article published in Medical Devices Evidence and Research in April 2022, The number of contrast-enhanced computed tomography (CT) examinations is rising worldwide each year. Because of the development of scanner technology and Multidetector CT (MDCT) availability, the time to conduct the scan has become more concise. A new CT injection system has been developed to maintain the fluid delivery benefits of a piston-based system (such as the Stellant CT injection system) but with the most elevated conceivable time efficiency, permitting the radiographer to spend less time handling the injector and disposables and more time concentrating on the patient. While the technical fluid delivery performance is very similar between this novel injection system and the current piston-based system, the major differences are in the workflow features.

In addition, the market players are applying the market strategies such as acquisition and product launches. For instance, in December 2021, to meet the demands of hospitals and imaging networks, Qaelum NV agreed with Ulrich GmbH & Co. KG in Ulm to merge their Contrast Management technology with Ulrich medical's contrast media injectors.

Geographical Analysis

North America region holds the largest market share of the global contrast media injectors market

North America dominates the market for contrast media injectors and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, a rising aging population, technological advancement and approval of products.

As per the American Association for the Surgery of Trauma data, in 2020, trauma accounted for nearly 40 Mn homicide and suicide deaths each year in the US that occurred due to trauma. The rising number of patients with trauma leads to increasing demand for contrast media injectors in the North American region.

In addition, the presence of a large number of key players and easily availability of products and services drive the market. For instance, Ulrich medical offers contrast media injectors for usage in computed tomography (CT) and magnetic resonance imaging (MRI).

Competitive Landscape

The contrast media injectors market is a moderately competitive presence of local and global companies. Some key players contributing to the market's growth are Bracco Imaging, Guerbet Group, Imaxeon, Medtronic, Nemoto, M. Schilling GmbH Medical Products, PTM-Network Services GmbH, Shenzhen Anke High-Tech, Ulrich Medical, Vivid Imaging among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the global contrast media injectors market's growth.

For instance,

In December 2021, Guerbet and Bracco Imaging collaborated for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.

Bracco Imaging

Overview:

Bracco Imaging is an Italian healthcare multinational company founded in 1927 and headquartered in Milan, Italy. The company developed specific contrast injectors for intravenous procedures in CT and MRI and for intraarterial procedures in Cardiac and or Peripheral intervention.

Product Portfolio:

CT Expres: It is a 3D Contrast Media Delivery System that is used for controlled automatic management, on the venous side of contrast media and saline, to human matters while experiencing examination by means of computed tomography (CT) scanner.

The global contrast media injectors market report would provide access to approximately 75+ market data tables, 75+ figures, and in the range of 250 (approximate) pages.